Diabète et endocrinologie
Enterprise-wide expertise from early phase to registrational studies
We deliver innovative, technology-enabled solutions with a patient-centric approach to advance clinical development in diabetes, obesity/metabolism and endocrinology.
Enhanced recruitment
We advance endocrinology drug and device development with our specialized focus on the right sites and the right treatments for patients.
Expertise where it counts
Access deep and broad enterprise-wide expertise in endocrinology indications supported by therapeutic area experts in medical, regulatory, strategy and operations.
Data-driven decision-making
Expect unique insights from unparalleled endocrinology data to support protocol and clinical plan design and deliver better outcomes.
Tailored solutions for endocrinology clinical trials
Advance your endocrinology drug, cell/gene therapy or device to market with the expertise and agility of Fortrea. We deliver support with early-phase adaptive trial design, site selection, patient identification and targeted services for late-phase endocrinology trials that help you bring treatments to patients faster. We serve as your committed partner with the expertise and experience to deliver a comprehensive trial solution that fits your organization's business and strategy.
Advancing your precision medicine
Our MDs and subject matter experts have helped bring precision medicines to market, from targeted therapies to immunotherapies to advanced cell and gene therapies. Our expertise enhances study designs and delivers operational efficiencies across the full range of development phases, and we provide novel solutions focused on CFR-compliant data aggregation-spanning CGM devices, SMBG and pediatric considerations in trials across issues of PK, blood volume and consent/assent.
Delivering agility at scale
Working with our dedicated, global endocrinology team, you can leverage our rich site performance database, operational experience with complex trial designs and established site relationships to reach your development goals faster. Throughout your development, we'll apply our tools and medical, scientific and regulatory expertise to navigate complexities and eliminate inefficiencies. Together, let's enable innovative, technology-driven solutions with a patient-centric approach as we deliver efficient clinical development plans and protocols in diabetes, obesity/metabolism and endocrinology.
Endocrinology experience that matters
In the last 5 years, we have supported:
Top indications
- Diabète de type 1
- Diabète de type 2
- Obésité
- Maladies rares
- Endocrine Disorders
Nos experts
Delivering strategic leadership
Un partenariat exceptionnel commence avec une équipe expérimentée. Browse the bios of our featured team members.
Plamen Penev, MD, PhD
Executive Medical Director
Plamen Penev, MD, PhD, is a Board-Certified endocrinologist and Executive Medical Director leading a group of five other endocrinologists in the Cardiovascular, Metabolic, Endocrine and Renal therapeutic areas at Fortrea.
Dr. Penev completed his PhD training at Northwestern University, followed by residency in Internal Medicine at Saint Louis University and fellowship in Endocrinology at the University of Chicago and has over 25 years of combined patient care and clinical research experience in academia and industry.
Mala Puri, MD
Directeur médical
Mala Puri, MD, is a Board-Certified Pediatric Endocrinologist and Senior Medical Director focused in the Cardiovascular, Metabolic, Endocrine and Renal therapeutic areas at Fortrea. Dr. Puri completed her residency training and fellowship in Pediatric Endocrinology at the Children's Hospital at Montefiore, New York and has over 20 years of combined clinical and research work in academia and industry including significant experience in global pediatric and rare disease studies.
The Fortrea study team has continued showing great engagement, performance, and collaboration with us. Both the Project Director and Project Manager along with their study team moved "mountains" to achieve the study goals. On top of their performance, it is really a pleasure on a personal level to work with such engaged and positive team members!
Large Pharma
Their study team moved “mountains” to achieve the study goals
The support and connections you need
Our global endocrinology team includes industry leaders in medical, operational and strategic fields with experience in novel cell therapies in T1DM, oral agents added to insulin in T1DM, studies with injectable assets and implantable infusion systems for hormone delivery, rare pediatric diseases and many others.
Our recent, ongoing and relevant experience in a large portfolio of endocrinology trials from early phase to registrational, includes novel cell and gene therapies. This includes our:
- Easing patient identification and increasing community awareness with strong connections to advocacy groups, investigators and organizations, such as Breakthrough T1D (formerly JDRF), ADA, PWSA and CHI.
- Robust experience in rare disorders appearing in childhood and adolescence along with unique capabilities in pituitary, adrenal and parathyroid hormone disorders